SCHEMBL13310475

SCHEMBL13310475

C=CCOC1C(=C)C(=O)O[C@@H]1CC

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ KAT2A Q92830 3/20 0.36
▸ POLB P06746 1/20 0.33
▸ FASN P49327 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13310479 1.00 KAT2A (0.36) KAT2APOLBFASN
SCHEMBL13310476 0.88 KAT2A (0.48) KAT2APOLBFASN
SCHEMBL12532836 0.88 KAT2A (0.48) KAT2APOLBFASN
SCHEMBL13310478 0.80 KAT2A (0.32) KAT2APOLB
SCHEMBL12532831 0.80 KAT2A (0.32) KAT2APOLB
SCHEMBL13310477 0.77 KAT2A (0.30) KAT2A
SCHEMBL12532837 0.77 KAT2A (0.30) KAT2A
SCHEMBL13434959 0.77 ALDH1A1 (0.34) —
SCHEMBL12532854 0.76 — —
SCHEMBL3947192 0.67 KAT2A (0.44) KAT2APOLBFASN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140194632-A1 Method for Screening for Compounds Selectively Interacting with RAD9 MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) 2014-07-10 — — US disclosed
US-20140194632-A1 Method for Screening for Compounds Selectively Interacting with RAD9 MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) 2014-07-10 — — US disclosed
US-8501431-B2 Method for screening for compounds selectively interacting with RAD9 MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) 2013-08-06 — — US disclosed
US-20100137618-A1 METHOD FOR SCREENING FOR COMPOUNDS SELECTIVELY INTERACTING WITH RAD9 MAGNACHEM INTERNATIONAL LABORATORIES, INC. 2010-06-03 — — US disclosed
US-20100137618-A1 METHOD FOR SCREENING FOR COMPOUNDS SELECTIVELY INTERACTING WITH RAD9 MAGNACHEM INTERNATIONAL LABORATORIES, INC. 2010-06-03 — — US disclosed
US-7323495-B2 Synthetic lactone formulations and method of use MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) 2008-01-29 — — US disclosed
US-7323495-B2 Synthetic lactone formulations and method of use MAGNACHEM INTERNATIONAL LABORATORIES, INC. (US) 2008-01-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137618-A1 METHOD FOR SCREENING FOR COMPOUNDS SELECTIVELY INTERACTING WITH RAD9 TP53, RPL19, HSPE1 KAT2A 3351/4885POLB 914/4885FASN 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback